Moleculin Biotech announces notification from USPTO regarding Annamycin

Moleculin Biotech announced it has received an Issue Notification from the United States Patent and Trademark Office, or USPTO, for U.S. Patent number 11,951,118 titled, “Preparation of Preliposomal Annamycin Lyophilizate” to be issued on April 9 to Moleculin and The University of Texas System Board of Regents. When issued, the patent will provide claims to compositions that contain Annamycin with a base patent term extending until June 2040, subject to extension to account for time required to fulfill regulatory requirements for FDA approval. Moleculin’s novel candidate for the treatment of acute myeloid leukemia and soft tissue sarcoma lung metastases uses a unique lipid-based delivery technology. In addition to the expected ‘118 patent, Moleculin has additional patent applications pending in the U.S. and in major jurisdictions worldwide. Annamycin is Moleculin’s next-generation anthracycline, initially expected to fulfill a significant unmet need for the 2nd line treatment of relapsed or refractory AML patients.